To include your compound in the COVID-19 Resource Center, submit it here.

CEP-37247: Phase I/II started

In January, Cephalon began a double-blind, placebo-controlled, U.S. Phase I/II trial to evaluate single doses

Read the full 156 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE